enGene Holdings Inc. (ENGN) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does enGene Holdings Inc. Do?
enGene Holdings Inc. (ENGN) is a small-cap company in the Healthcare sector, operating within the Pharmaceutical Products industry. The stock has a market capitalization of $453M, making it a notable participant in its sector. Investors researching ENGN stock will find a comprehensive, data-driven analysis below covering valuation, profitability, growth, dividends, and peer comparisons for the Pharmaceutical Products space.
enGene Holdings Inc. (ENGN) Stock Rating — Reduce (April 2026)
As of April 2026, enGene Holdings Inc. receives a Reduce rating with a composite score of 37.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ENGN ranks #3,707 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, enGene Holdings Inc. ranks #614 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ENGN Stock Price and 52-Week Range
enGene Holdings Inc. (ENGN) currently trades at $7.28. The stock gained $0.01 (0.1%) in the most recent trading session. The 52-week high for ENGN is $12.25, which means the stock is currently trading -40.6% from its annual peak. The 52-week low is $2.65, putting the stock 174.7% above its annual trough. Recent trading volume was 2K shares, suggesting relatively thin trading activity.
Is ENGN Overvalued or Undervalued? — Valuation Analysis
enGene Holdings Inc. (ENGN) carries a value factor score of 26/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 16.52x, compared to the Healthcare sector average of 23.63x — a discount of 30%. The price-to-book ratio stands at 1.74x, versus the sector average of 2.75x.
At current multiples, enGene Holdings Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
enGene Holdings Inc. Profitability — ROE, Margins, and Quality Score
enGene Holdings Inc. (ENGN) earns a quality factor score of 28/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -35.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -29.3% versus the sector average of -33.1%.
Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
ENGN Debt, Balance Sheet, and Financial Health
enGene Holdings Inc. has a debt-to-equity ratio of 20.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 11.75x, indicating strong short-term liquidity. Total debt on the balance sheet is $23M. Cash and equivalents stand at $50M.
ENGN has a beta of 0.70, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for enGene Holdings Inc. is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
enGene Holdings Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, enGene Holdings Inc. reported revenue of $0 and earnings per share (EPS) of $0.44. Net income for the quarter was $-99M. Operating income came in at $-105M.
In Q1 2026, enGene Holdings Inc. reported revenue of $0 and earnings per share (EPS) of $0.44. Net income for the quarter was $-30M. Operating income came in at $-31M.
In FY 2025, enGene Holdings Inc. reported revenue of $0 and earnings per share (EPS) of $2.29. Net income for the quarter was $-117M. Operating income came in at $-123M.
In Q3 2025, enGene Holdings Inc. reported revenue of $0 and earnings per share (EPS) of $0.57. Net income for the quarter was $-29M. Operating income came in at $-30M.
Over the past 8 quarters, enGene Holdings Inc. has experienced revenue contraction from $0 to $0. Investors analyzing ENGN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ENGN Dividend Yield and Income Analysis
enGene Holdings Inc. (ENGN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
ENGN Momentum and Technical Analysis Profile
enGene Holdings Inc. (ENGN) has a momentum factor score of 50/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 65/100 reflects moderate short selling activity.
ENGN vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, enGene Holdings Inc. (ENGN) ranks #614 out of 838 stocks based on the Blank Capital composite score. This places ENGN in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing ENGN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ENGN vs S&P 500 (SPY) comparison to assess how enGene Holdings Inc. stacks up against the broader market across all factor dimensions.
ENGN Next Earnings Date
No upcoming earnings date has been announced for enGene Holdings Inc. (ENGN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ENGN? — Investment Thesis Summary
The quantitative profile for enGene Holdings Inc. suggests caution. The quality score of 28/100 flags below-average profitability. The value score of 26/100 indicates premium valuation. High volatility (stability score 35/100) increases portfolio risk.
In summary, enGene Holdings Inc. (ENGN) earns a Reduce rating with a composite score of 37.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ENGN stock.
Related Resources for ENGN Investors
Explore more research and tools: ENGN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ENGN head-to-head with peers: ENGN vs AZN, ENGN vs SLGL, ENGN vs VMD.